Novo Nordisk (NVO.N) has raised its adjusted sales and operating profit forecasts for 2026, expecting adjusted EBIT growth of -6% to 0% for the fiscal year. Adjusted sales for the second quarter of 2026 are expected to grow by 7% at constant currency, and adjusted operating profit by 11% at constant currency.